Synthesis, molecular docking study, and evaluation of the antiproliferative action of a new group of propargylthio- and propargylselenoquinolines
- 335 Downloads
This study describes the synthesis of a new group of halogenopropargylthio-, dipropargylthio-, and halogenopropargylseleno-quinoline derivatives. The ability of all of the synthesized compounds to inhibit the proliferation of the T-47D, MCF-7, MDA-MB-231, and SNB-19 cell lines was determined with the WST-1 assay. The normal fibroblast cell line (HFF-1) was used as a control. The cytotoxic properties of these new, modified propargylquinoline derivatives were comparable to those of cisplatin. The most active compounds, 4,7-dipropargylthiquinoline (8b) and 7-chloro-4-propargylselenoquinoline (5b), were docked into the binding site of human CYP1A1 and CYP1B1. Our data indicate that these derivatives may present promising chemotherapeutic agents, possibly targeting CYP1s pathway.
KeywordsPropargylthioquinolines Propargylselenoquinolines Dipropargylthioquinolines Anticancer activity Molecular docking
This research was supported by the Medical University of Silesia, Grant No. KNW-1-032/K/3/0.
- Gajjar K, Martin-Hirsch PL, Martin FL (2012) CYP1B1 and hormone-induced ancer. Cancer Lett 324:13–30Google Scholar
- Hevir N, Šinkovec J, Rižner TL (2011) Disturbed expression of phase I and phase II estrogen-metabolizing enzymes in endometrial cancer: lower levels of CYP1B1 and increased expression of S-COMT. Mol Cell Endocrinol 331:158–167Google Scholar
- Shimada T, Tanaka NK, Takenaka S, Imai Y, Hopkins NE, Foroozesh MK, Alworth WL, Yamazaki H, Guengerich FP, Komori M (2008) Interaction of polycyclic aromatic hydrocarbons with human cytochrome P450 1B1 in inhibiting catalytic activity. Chem Res Toxicol 21(12):2313–2323PubMedCentralCrossRefPubMedGoogle Scholar
- Silva IS (1999) Cancer epidemiology: principles and methods. International Agency for Research on Cancer (IARC), LyonGoogle Scholar
- Sos ML, Koker M, Weir BA, Heynck S, Rabinovsky R, Zander T, Seeger JM, Weiss J, Fischer F, Frommolt P, Michel K, Peifer M, Mermel C, Girard L, Peyton M, Gazdar AF, Minna JD, Garraway LA, Kashkar H, Pao W, Meyerson M, Thomas RK (2009) PTEN loss contributes to erlotinib resistance in EGFR-mutant lung cancer by activation of Akt and EGFR. Cancer Res 69(8):3256–3261PubMedCentralCrossRefPubMedGoogle Scholar